Mini-array of multiple tumor-associated antigens (TAAs) in the immunodiagnosis of breast cancer

Oncology Letters

Volumn 5, Issue 2, 2013, Pages 663-668

  Ye, Hua ^a,b   Sun, Changqing ^a   Ren, Pengfei ^a,b   Dai, Liping ^a,b   Peng, Bo ^b   Wang, Kaijuan ^a   Qian, Wei ^b   Zhang, Jianying ^a,b  

^a ZHENGZHOU UNIVERSITY   (China)

^b UNIVERSITY OF TEXAS AT EL PASO   (United States)

Author keywords

Autoantibodies; Breast cancer; Immunodiagnosis; Tumor associated antigens

Indexed keywords

AUTOANTIBODY; CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; INOSINE PHOSPHATE; MYC PROTEIN; PROTEIN P16; PROTEIN P53; PROTEIN P62; SURVIVIN; TUMOR ANTIGEN;

ANTIBODY DETECTION; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOBLOTTING; PREDICTIVE VALUE; PREVALENCE; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; WESTERN BLOTTING;

EID: 84871604202     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.1062     Document Type: Article

References (25)

1. Shin HR, Joubert C, Boniol M, et al: Recent trends and patterns in breast cancer incidence among Eastern and Southeastern Asian women. Cancer Causes Control 21: 1777-1785, 2010.
2. American Cancer Society: Cancer Facts & Figures 2007. ACS Publication, Atlanta GA, 2007.
3. Tan EM and Zhang J: Autoantibodies to tumor-associated antigens: reporters from the immune system. Immunol Rev 222: 328-340, 2008.
4. Zhang JY and Tan EM: Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors. Expert Rev Mol Diagn 10: 321-328, 2010.
5. Soussi T: p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 60: 1777-1788, 2000.
6. Looi K, Megliorino R, Shi FD, Peng XX, Chen Y and ZhangJY: Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. Oncol Rep 16: 1105-1110, 2006.
7. Yamamoto A, Shimizu E, Takeuchi E, et al: Infrequent presence of anti-c-Myc antibodies and absence of c-Myc oncoprotein in sera from lung cancer patients. Oncology 56: 129-133, 1999.
8. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S and Cheever MA: High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 15: 3363-3367, 1997.
9. Zhang JY, Chan EK, Peng XX and Tan EM: A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma. J Exp Med 189: 1101-1110, 1999.
10. Doyle GA, Bourdeau-Heller JM, Coulthard S, Meisner LF and Ross J: Amplification in human breast cancer of a gene encoding a c-myc mRNA-binding protein. Cancer Res 60: 2756-2759, 2000.
11. Soo Hoo L, Zhang JY and Chan EK: Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer. Oncogene 21: 5006-5015, 2002.
12. Ambrosini G, Adida C and Altieri DC: A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3: 917-921, 1997.
13. Megliorino R, Shi FD, Peng XX, et al: Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection. Cancer Detect Prev 29: 241-248, 2005.
14. Daniels T, Zhang J, Gutierrez I, et al: Antinuclear autoantibodies in prostate cancer: immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis. Prostate 62: 14-26, 2005.
15. Crawford LV, Pim DC and Bulbrook RD: Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 30: 403-408, 1982.
16. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF and Carbone DP: Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 52: 4168-4174, 1992.
17. Anderson KS and LaBaer J: The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res 4: 1123-1133, 2005.
18. Zhang JY, Casiano CA, Peng XX, Koziol JA, Chan EK and TanEM: Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev 12: 136-143, 2003.
19. Chen WQ: Assessing the validity and reliability of screening test. In: Epidemiology. Li LM (ed). Publishing Company of the People's Health, Beijing, pp289-292, 2004.
20. Koziol JA, Zhang JY, Casiano CA, et al: Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 9: 5120-5126, 2003.
21. Zhang JY, Megliorino R, Peng XX, Tan EM, Chen Y and Chan EK: Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma. J Hepatol 46: 107-114, 2007.
22. Chen Y, Zhou Y, Qiu S, et al: Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma. Cancer Lett 289: 32-39, 2010.
23. Liu W, Wang P, Li Z, et al: Evaluation of tumour-associated antigen (TAA) miniarray in immunodiagnosis of colon cancer. Scand J Immunol 69: 57-63, 2009.
24. Chen Y, Lin P, Qiu S, et al: Autoantibodies to Ca2+ binding protein Calnuc is a potential marker in colon cancer detection. Int J Oncol 30: 1137-1144, 2007.
25. Li L, Wang K, Dai L, Wang P, Peng XX and Zhang JY: Detection of autoantibodies to multiple tumor-associated antigens in the immunodiagnosis of ovarian cancer. Mol Med Rep 1: 589-594, 2008.